Even during the COVID-19 pandemic, the Competition Bureau is working tirelessly to ensure that Canadians have access to cost-saving prescription generic medicines.
On April 2, 2020, the Bureau issued a statement in which it mentions that any further obstruction to the manufacture of generic alternatives will not be tolerated.
For the second time, the Bureau investigated a branded pharmaceutical company and found that it refused to supply samples of brand name drugs – also known as Canadian Reference Products (CRPs) – to generic manufacturers. This practice ultimately delays the entry of generic products on the market.
Read the full statement here.